MDT-BRIDGE in Resectable and Borderline Resectable NSCLC
Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

LungenClinic Grosshansdorf
Prof. Martin Reck heads the Department of Thoracic Oncology at LungenClinic Grosshansdorf in Germany. He has led pivotal first-line immunotherapy trials in metastatic NSCLC, including KEYNOTE-024, and continues to drive evidence generation across the lung cancer treatment landscape. He is a frequent speaker at major international congresses.
Martin Reck
Programme Roster